Joint BioEnergy Institute announced that Jay Keasling, PhD, CEO and Director of New Pathway Development, is the recipient of two prestigious awards:
- Humboldt Research Award for his achievements and expertise in biochemistry, genetics of microorganisms, and applied microbiology.
-
Bakar Prize to engineer bacteria to produce probiotics to treat skin diseases caused by the bacteria Staphylococcus aureus.
4DMT Molecular Therapeutics
- 4DMT presented positive interim data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 demonstrating favorable tolerability and clinical activity in Wet AMD.
-
In interview with Nature Portfolio, CEO David Kirn, MD, expanded on 4DMT's use of directed evolution to significantly improve genetic delivery to target cells and tissues, transforming treatments for patients with severe common diseases.
- 4DMT announced pricing of upsized public offering of common stock (Nasdaq: FDMT).
ABPDU (Advanced Biofuels and Bioproducts Process Development Unit) announced that ABPDU and its partners had developed bio-derived ionic liquids derived from lignin, a natural polymer found in plant cell walls. The research was supported by an award from the U.S. Dept. of Energy's Office of Technology Transitions' Technology Commercialization Fund.
Activate announced in its impact stats for 2023 that last year alone, Activate Fellows raised $263M in follow-on funding, created over 600 jobs, secured 300 corporate partnerships, and won nearly 80 awards. Activate received over 800 fellowship applicants and welcome their most diverse cohort yet, with 37% women and $43 founders of color.
Kyverna Therapeutics
- Kyverna and Stanford University agree to evaluate KYV-101 in patients with non-relapsing and progressive forms of Multiple Sclerosis.
- Kyverna announced closing of its initial public offering and full exercise of underwriters' option to purchase additional shares (Nasdaq: KYTX).
Metagenomi announced the closing of its initial public offering (Nasdaq: MGX).
Nutcracker Therapeutics announced it will present data on mRNA Drug Candidate and Immunomodulatory Cytokine at the 2024 American Association for Cancer Research Annual Meeting.
Pivot Bio was named a Fast Company Most Innovative Company for their work to harness the power of nature to solve one of the biggest challenges facing modern agriculture.
Sangamo Therapeutics
- Announced U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease.
- Announced their novel neurotropic AAV capsid that demonstrated industry-leading blood brain penetration and brain transduction in non-human primates following intravenous administration.
|